调强放疗联合替莫唑胺治疗颅内恶性胶质瘤术后临床观察  

Clinical observation on intensity-modulated radiotherapy concurrent chemotherapy combined with Temozolomide in the treatment of postoperative malignant gliomas

作　　者：陈达桂[1] 李桂生[1] 黄海欣[1] 黄东宁[1] 

机构地区：[1]广西医科大学第四附属医院肿瘤科,广西柳州545005

出　　处：《中国医药导报》2012年第8期76-77,80,共3页China Medical Herald

摘　　要：目的探讨调强放射治疗联合替莫唑胺化疗综合治疗恶性脑胶质瘤的疗效及其安全性。方法将46例颅内恶性胶质瘤术后患者随机分为单纯调强放疗组(RT组)和调强放疗联合替莫唑胺化疗组(RT+TMZ组),各23例。两组均在术后开始接受调强放射治疗,RT+TMZ组加服TMZ化疗。评价两组患者1、2、3年生存率,中位生存时间及近、远期不良反应发生情况。结果 RT+TMZ组的1、2、3年生存率及中位生存时间均高于RT组(均P<0.05)。发生Ⅲ度以上白细胞下降、急性及晚期放射性脑损伤等不良反应,两组比较差异无统计学意义。结论调强放疗联合替莫唑胺化疗可提高恶性脑胶质瘤患者治疗有效率,无严重不良反应发生,是一种安全、有效的治疗手段。Objective To investigate the efficacy and safety of intensity-modulated radiotherapy（IMRT） with concurrent temozolomide（TMZ） chemotherapy for treatment of postoperative malignant glioma.Methods 46 postoperative patients with malignant glioma were randomly divided into two groups,each group was 23 patients.Patients in chemoradiotherapy group were treated with IMRT along with concurrent TMZ after surgery,while patients in the radiotherapy group received radiotherapy alone.The 1-year,2-year,3-year survival rate,median survival time and short-term,long-term adverse effects of two groups were evaluated.Results The 1-year,2-year,3-year survival rate and median survival time in the chemoradiotherapy group were significantly better compared to the radiotherapy alone group（P 0.05）.There were no significant differences in adverse effects between the two groups,such as leucocytopenia over Ⅲ degree,acute and late radiation-induced brain injury.Conclusion IMRT in combination with TMZ can improve treatment efficiency,no serious adverse events,and is a safe and effective cure for patients with postoperative malignant glioma.

关 键 词：调强放疗 替莫唑胺 颅内恶性胶质瘤 

分 类 号：R739.41[医药卫生—肿瘤]